Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Infertility, Male | 118 | 2024 | 287 | 19.250 |
Why?
|
Testosterone | 85 | 2025 | 591 | 17.290 |
Why?
|
Hypogonadism | 51 | 2020 | 309 | 12.210 |
Why?
|
Hormone Replacement Therapy | 28 | 2025 | 211 | 7.140 |
Why?
|
Azoospermia | 22 | 2023 | 47 | 6.660 |
Why?
|
Varicocele | 33 | 2020 | 60 | 6.580 |
Why?
|
Spermatozoa | 49 | 2023 | 241 | 6.000 |
Why?
|
Vasovasostomy | 19 | 2018 | 23 | 4.920 |
Why?
|
Erectile Dysfunction | 28 | 2023 | 205 | 4.670 |
Why?
|
Androgens | 16 | 2020 | 292 | 3.890 |
Why?
|
Spermatogenesis | 30 | 2024 | 170 | 3.520 |
Why?
|
Male | 349 | 2025 | 65619 | 3.450 |
Why?
|
Sperm Count | 39 | 2024 | 89 | 3.300 |
Why?
|
Shift Work Schedule | 6 | 2020 | 25 | 3.160 |
Why?
|
Chorionic Gonadotropin | 11 | 2024 | 79 | 3.070 |
Why?
|
Microsurgery | 11 | 2019 | 72 | 3.060 |
Why?
|
Testis | 44 | 2023 | 424 | 3.060 |
Why?
|
Vasectomy | 11 | 2018 | 17 | 3.040 |
Why?
|
Sperm Injections, Intracytoplasmic | 15 | 2021 | 45 | 3.000 |
Why?
|
Oligospermia | 41 | 2016 | 60 | 2.910 |
Why?
|
Penile Induration | 9 | 2024 | 37 | 2.850 |
Why?
|
Sperm Motility | 29 | 2019 | 107 | 2.720 |
Why?
|
Reproductive Techniques, Assisted | 10 | 2024 | 74 | 2.670 |
Why?
|
Urology | 7 | 2025 | 84 | 2.570 |
Why?
|
Fertilization in Vitro | 25 | 2019 | 160 | 2.490 |
Why?
|
Penis | 13 | 2022 | 102 | 2.450 |
Why?
|
Humans | 358 | 2025 | 133290 | 2.430 |
Why?
|
Fertility | 16 | 2019 | 266 | 2.420 |
Why?
|
Anal Canal | 6 | 2013 | 83 | 2.260 |
Why?
|
Semen Analysis | 13 | 2020 | 31 | 2.210 |
Why?
|
Estradiol | 12 | 2017 | 551 | 2.070 |
Why?
|
Semen | 23 | 2023 | 79 | 2.070 |
Why?
|
Follicle Stimulating Hormone | 28 | 2024 | 194 | 1.970 |
Why?
|
Vas Deferens | 12 | 2021 | 24 | 1.930 |
Why?
|
Pregnancy Rate | 4 | 2017 | 38 | 1.880 |
Why?
|
Prostatic Neoplasms | 18 | 2025 | 1626 | 1.860 |
Why?
|
Paternal Age | 6 | 2024 | 17 | 1.820 |
Why?
|
Lower Urinary Tract Symptoms | 5 | 2019 | 38 | 1.790 |
Why?
|
Adult | 127 | 2024 | 31851 | 1.730 |
Why?
|
Libido | 7 | 2019 | 36 | 1.690 |
Why?
|
Patient Satisfaction | 6 | 2024 | 502 | 1.680 |
Why?
|
Anabolic Agents | 6 | 2014 | 15 | 1.650 |
Why?
|
Genitalia, Male | 5 | 2014 | 39 | 1.630 |
Why?
|
Fathers | 5 | 2024 | 73 | 1.540 |
Why?
|
Sperm Retrieval | 7 | 2023 | 11 | 1.510 |
Why?
|
Sexual Dysfunction, Physiological | 9 | 2018 | 85 | 1.450 |
Why?
|
Urologic Surgical Procedures, Male | 7 | 2019 | 37 | 1.380 |
Why?
|
Penile Erection | 10 | 2023 | 85 | 1.340 |
Why?
|
Sleep Disorders, Circadian Rhythm | 2 | 2020 | 17 | 1.340 |
Why?
|
Scrotum | 7 | 2013 | 28 | 1.300 |
Why?
|
Retrospective Studies | 54 | 2025 | 17380 | 1.280 |
Why?
|
Microbial Collagenase | 6 | 2024 | 11 | 1.280 |
Why?
|
Work Schedule Tolerance | 2 | 2020 | 42 | 1.270 |
Why?
|
Middle Aged | 78 | 2025 | 29237 | 1.260 |
Why?
|
Reproduction | 4 | 2016 | 245 | 1.250 |
Why?
|
Male Urogenital Diseases | 3 | 2021 | 15 | 1.210 |
Why?
|
Organ Transplantation | 3 | 2020 | 185 | 1.200 |
Why?
|
Sexual Behavior | 5 | 2016 | 248 | 1.160 |
Why?
|
Ejaculatory Ducts | 7 | 2019 | 10 | 1.150 |
Why?
|
Penile Prosthesis | 5 | 2022 | 40 | 1.140 |
Why?
|
Occupational Diseases | 3 | 2019 | 75 | 1.140 |
Why?
|
Infertility | 5 | 2024 | 81 | 1.120 |
Why?
|
Fertility Agents, Male | 3 | 2016 | 5 | 1.080 |
Why?
|
Quality of Life | 9 | 2022 | 2120 | 1.060 |
Why?
|
Andrology | 2 | 2016 | 2 | 1.040 |
Why?
|
Eunuchism | 2 | 2016 | 7 | 1.000 |
Why?
|
Abortion, Habitual | 2 | 2016 | 17 | 0.980 |
Why?
|
Fees, Medical | 1 | 2025 | 7 | 0.970 |
Why?
|
Luteinizing Hormone | 17 | 2018 | 137 | 0.960 |
Why?
|
Surveys and Questionnaires | 18 | 2024 | 3983 | 0.950 |
Why?
|
Aneuploidy | 3 | 2016 | 145 | 0.940 |
Why?
|
Cryptorchidism | 9 | 2014 | 38 | 0.930 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2025 | 39 | 0.930 |
Why?
|
Urologic Surgical Procedures | 1 | 2025 | 59 | 0.930 |
Why?
|
Sleep | 3 | 2016 | 368 | 0.910 |
Why?
|
Semen Preservation | 5 | 2022 | 9 | 0.910 |
Why?
|
Dihydrotestosterone | 3 | 2015 | 71 | 0.910 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2025 | 62 | 0.900 |
Why?
|
Gynecology | 1 | 2025 | 128 | 0.850 |
Why?
|
Fertility Preservation | 3 | 2022 | 55 | 0.850 |
Why?
|
Men's Health | 3 | 2021 | 21 | 0.850 |
Why?
|
Neoplasms | 11 | 2022 | 3006 | 0.850 |
Why?
|
Treatment Outcome | 37 | 2024 | 12957 | 0.840 |
Why?
|
Posthumous Conception | 2 | 2013 | 3 | 0.840 |
Why?
|
Practice Patterns, Physicians' | 2 | 2020 | 766 | 0.800 |
Why?
|
Epididymis | 9 | 2013 | 63 | 0.770 |
Why?
|
Pregnancy | 28 | 2019 | 7487 | 0.770 |
Why?
|
Prostatectomy | 10 | 2013 | 357 | 0.770 |
Why?
|
Reproductive Health | 3 | 2021 | 47 | 0.770 |
Why?
|
Office Visits | 3 | 2015 | 78 | 0.740 |
Why?
|
Congenital Abnormalities | 3 | 2019 | 290 | 0.740 |
Why?
|
Cough | 1 | 2022 | 96 | 0.730 |
Why?
|
Medicare | 1 | 2025 | 464 | 0.730 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2014 | 47 | 0.700 |
Why?
|
Ultrasonography, Doppler, Duplex | 2 | 2018 | 44 | 0.700 |
Why?
|
Orchiectomy | 3 | 2019 | 53 | 0.700 |
Why?
|
Seasons | 2 | 2013 | 329 | 0.700 |
Why?
|
Reproductive Medicine | 3 | 2018 | 19 | 0.690 |
Why?
|
Thrombosis | 3 | 2015 | 534 | 0.680 |
Why?
|
Cryopreservation | 7 | 2022 | 75 | 0.680 |
Why?
|
In Situ Hybridization, Fluorescence | 7 | 2016 | 790 | 0.670 |
Why?
|
Receptors, Androgen | 8 | 2018 | 433 | 0.670 |
Why?
|
DNA Fragmentation | 4 | 2016 | 61 | 0.670 |
Why?
|
Vasodilator Agents | 4 | 2014 | 209 | 0.660 |
Why?
|
Estrogen Antagonists | 2 | 2020 | 105 | 0.660 |
Why?
|
Seminal Vesicles | 3 | 2017 | 56 | 0.660 |
Why?
|
Prostate-Specific Antigen | 7 | 2025 | 272 | 0.650 |
Why?
|
Prostatic Hyperplasia | 3 | 2018 | 118 | 0.650 |
Why?
|
Infertility, Female | 2 | 2016 | 148 | 0.650 |
Why?
|
Enclomiphene | 2 | 2016 | 3 | 0.640 |
Why?
|
Dietary Supplements | 4 | 2020 | 498 | 0.640 |
Why?
|
Age Factors | 9 | 2018 | 2971 | 0.640 |
Why?
|
Asthenozoospermia | 1 | 2019 | 6 | 0.630 |
Why?
|
Physicians | 3 | 2024 | 626 | 0.620 |
Why?
|
Critical Pathways | 2 | 2018 | 79 | 0.620 |
Why?
|
Drug Monitoring | 2 | 2020 | 180 | 0.620 |
Why?
|
Smoking | 2 | 2015 | 1135 | 0.620 |
Why?
|
Radiation Injuries | 2 | 2014 | 164 | 0.610 |
Why?
|
Cohort Studies | 11 | 2020 | 5174 | 0.600 |
Why?
|
Penile Diseases | 1 | 2018 | 11 | 0.600 |
Why?
|
Prostheses and Implants | 2 | 2019 | 158 | 0.600 |
Why?
|
Exosomes | 1 | 2019 | 56 | 0.600 |
Why?
|
Extracellular Vesicles | 1 | 2019 | 56 | 0.590 |
Why?
|
Biomarkers | 4 | 2024 | 3402 | 0.580 |
Why?
|
Insurance Coverage | 2 | 2016 | 124 | 0.580 |
Why?
|
Clomiphene | 2 | 2016 | 12 | 0.570 |
Why?
|
Doping in Sports | 3 | 2014 | 8 | 0.570 |
Why?
|
Prosthesis Implantation | 1 | 2019 | 146 | 0.570 |
Why?
|
Fatigue | 2 | 2016 | 203 | 0.570 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2017 | 353 | 0.560 |
Why?
|
Aging | 3 | 2014 | 1298 | 0.560 |
Why?
|
Aged | 38 | 2025 | 21619 | 0.550 |
Why?
|
Ejaculation | 11 | 2003 | 22 | 0.550 |
Why?
|
Teratozoospermia | 1 | 2017 | 4 | 0.540 |
Why?
|
Human Growth Hormone | 1 | 2017 | 78 | 0.540 |
Why?
|
Impotence, Vasculogenic | 2 | 2014 | 9 | 0.540 |
Why?
|
United States | 21 | 2025 | 11633 | 0.530 |
Why?
|
Female | 65 | 2025 | 71345 | 0.530 |
Why?
|
Pregnancy Outcome | 3 | 2012 | 624 | 0.530 |
Why?
|
Time-to-Treatment | 1 | 2018 | 201 | 0.530 |
Why?
|
Work | 1 | 2016 | 12 | 0.530 |
Why?
|
Health Care Costs | 3 | 2016 | 402 | 0.520 |
Why?
|
Administration, Oral | 3 | 2016 | 727 | 0.510 |
Why?
|
Men | 1 | 2016 | 7 | 0.510 |
Why?
|
Sperm Banks | 3 | 2013 | 4 | 0.510 |
Why?
|
Genetic Testing | 5 | 2020 | 1085 | 0.510 |
Why?
|
Injections, Intralesional | 2 | 2024 | 49 | 0.510 |
Why?
|
Sex Hormone-Binding Globulin | 7 | 2017 | 44 | 0.510 |
Why?
|
Androstenediol | 1 | 2015 | 1 | 0.490 |
Why?
|
Sertoli Cells | 18 | 2003 | 77 | 0.490 |
Why?
|
Androstenedione | 1 | 2015 | 12 | 0.490 |
Why?
|
Trinucleotide Repeats | 3 | 2013 | 108 | 0.490 |
Why?
|
Testicular Diseases | 7 | 2016 | 12 | 0.490 |
Why?
|
Dehydroepiandrosterone | 1 | 2015 | 29 | 0.480 |
Why?
|
Chromosome Aberrations | 5 | 2016 | 625 | 0.480 |
Why?
|
Iron | 2 | 2018 | 303 | 0.480 |
Why?
|
Follow-Up Studies | 14 | 2020 | 5481 | 0.470 |
Why?
|
Spinal Cord Injuries | 4 | 2016 | 331 | 0.460 |
Why?
|
Referral and Consultation | 2 | 2018 | 571 | 0.460 |
Why?
|
Risk Factors | 18 | 2019 | 11006 | 0.460 |
Why?
|
Carbolines | 1 | 2014 | 9 | 0.460 |
Why?
|
Body Fluids | 1 | 2015 | 49 | 0.460 |
Why?
|
Polycythemia | 1 | 2015 | 44 | 0.450 |
Why?
|
Andropause | 1 | 2014 | 3 | 0.450 |
Why?
|
Child Mortality | 1 | 2014 | 25 | 0.450 |
Why?
|
Genetic Counseling | 1 | 2016 | 244 | 0.440 |
Why?
|
Mental Health | 1 | 2017 | 370 | 0.440 |
Why?
|
Walking | 1 | 2016 | 236 | 0.440 |
Why?
|
Sperm-Ovum Interactions | 13 | 1997 | 23 | 0.440 |
Why?
|
Sleep Wake Disorders | 1 | 2016 | 186 | 0.440 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2014 | 61 | 0.430 |
Why?
|
Young Adult | 13 | 2019 | 9872 | 0.430 |
Why?
|
Severity of Illness Index | 8 | 2019 | 3058 | 0.430 |
Why?
|
Prescription Drugs | 1 | 2014 | 59 | 0.420 |
Why?
|
Gonadotropins | 2 | 2012 | 33 | 0.420 |
Why?
|
Muscle Strength | 1 | 2014 | 97 | 0.420 |
Why?
|
Educational Status | 1 | 2014 | 293 | 0.420 |
Why?
|
Infant Mortality | 1 | 2014 | 180 | 0.410 |
Why?
|
Organizational Policy | 1 | 2013 | 56 | 0.410 |
Why?
|
Clinical Protocols | 2 | 2013 | 244 | 0.400 |
Why?
|
Sex Ratio | 1 | 2012 | 13 | 0.400 |
Why?
|
Mortality | 1 | 2014 | 261 | 0.400 |
Why?
|
Vascular Diseases | 1 | 2014 | 158 | 0.390 |
Why?
|
Patients | 1 | 2013 | 127 | 0.390 |
Why?
|
Fallopian Tubes | 1 | 2013 | 78 | 0.390 |
Why?
|
Cell Communication | 1 | 2013 | 186 | 0.380 |
Why?
|
Prospective Studies | 16 | 2023 | 6629 | 0.380 |
Why?
|
Physical Examination | 5 | 2020 | 163 | 0.370 |
Why?
|
Choice Behavior | 1 | 2013 | 137 | 0.370 |
Why?
|
Emotions | 1 | 2014 | 365 | 0.370 |
Why?
|
Nomograms | 1 | 2011 | 40 | 0.370 |
Why?
|
Paternity | 1 | 2011 | 8 | 0.370 |
Why?
|
Evidence-Based Medicine | 2 | 2014 | 666 | 0.370 |
Why?
|
Time Factors | 19 | 2024 | 6562 | 0.360 |
Why?
|
Medical History Taking | 5 | 2020 | 117 | 0.360 |
Why?
|
Endothelium, Vascular | 1 | 2014 | 510 | 0.360 |
Why?
|
Body Composition | 1 | 2014 | 564 | 0.360 |
Why?
|
Cardiovascular Diseases | 4 | 2017 | 2064 | 0.350 |
Why?
|
Metabolic Syndrome | 1 | 2014 | 365 | 0.350 |
Why?
|
Penile Implantation | 1 | 2011 | 25 | 0.350 |
Why?
|
Family Planning Services | 2 | 2024 | 39 | 0.350 |
Why?
|
Sexual Partners | 1 | 2011 | 87 | 0.350 |
Why?
|
Myocardial Ischemia | 1 | 2014 | 362 | 0.350 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 1192 | 0.340 |
Why?
|
Testicular Neoplasms | 4 | 2019 | 135 | 0.340 |
Why?
|
Socioeconomic Factors | 2 | 2014 | 914 | 0.340 |
Why?
|
Spermatic Cord | 2 | 2009 | 12 | 0.330 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2013 | 891 | 0.320 |
Why?
|
Specimen Handling | 6 | 2000 | 149 | 0.310 |
Why?
|
Anthropometry | 1 | 2009 | 202 | 0.310 |
Why?
|
Phosphodiesterase Inhibitors | 3 | 2014 | 52 | 0.300 |
Why?
|
Risk Assessment | 7 | 2017 | 3665 | 0.300 |
Why?
|
Demography | 1 | 2009 | 246 | 0.300 |
Why?
|
Clinical Trials as Topic | 5 | 2018 | 1150 | 0.300 |
Why?
|
Incidence | 9 | 2020 | 3381 | 0.300 |
Why?
|
Attitude of Health Personnel | 3 | 2020 | 713 | 0.290 |
Why?
|
Decision Making | 1 | 2013 | 693 | 0.290 |
Why?
|
Injections, Intramuscular | 2 | 2022 | 197 | 0.290 |
Why?
|
Gels | 3 | 2014 | 73 | 0.280 |
Why?
|
Piperazines | 4 | 2008 | 257 | 0.280 |
Why?
|
Risk | 4 | 2019 | 833 | 0.280 |
Why?
|
Texas | 5 | 2019 | 3677 | 0.280 |
Why?
|
Insulin | 2 | 2012 | 1246 | 0.280 |
Why?
|
Biopsy | 13 | 2025 | 1300 | 0.280 |
Why?
|
Oxidative Stress | 1 | 2013 | 860 | 0.280 |
Why?
|
Societies, Medical | 2 | 2018 | 758 | 0.280 |
Why?
|
Cross-Sectional Studies | 7 | 2014 | 3733 | 0.280 |
Why?
|
Mutation | 3 | 2014 | 6267 | 0.270 |
Why?
|
Case-Control Studies | 7 | 2017 | 3629 | 0.270 |
Why?
|
Egg Yolk | 2 | 2020 | 4 | 0.270 |
Why?
|
Mental Disorders | 1 | 2014 | 876 | 0.270 |
Why?
|
Sterilization Reversal | 2 | 2018 | 5 | 0.260 |
Why?
|
Drug Implants | 4 | 2013 | 44 | 0.260 |
Why?
|
Myocardial Infarction | 1 | 2014 | 1084 | 0.260 |
Why?
|
Health Care Surveys | 2 | 2020 | 291 | 0.250 |
Why?
|
History, 20th Century | 3 | 2018 | 397 | 0.250 |
Why?
|
Inflation, Economic | 1 | 2025 | 1 | 0.240 |
Why?
|
Critical Illness | 1 | 2010 | 617 | 0.240 |
Why?
|
Genetic Diseases, Inborn | 2 | 2007 | 453 | 0.230 |
Why?
|
Urinary Bladder | 6 | 1998 | 251 | 0.230 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 1314 | 0.230 |
Why?
|
Clinical Competence | 3 | 2020 | 1057 | 0.230 |
Why?
|
Chromosomes, Human, Y | 4 | 2014 | 50 | 0.220 |
Why?
|
Medical Illustration | 1 | 2004 | 19 | 0.220 |
Why?
|
Watchful Waiting | 1 | 2025 | 77 | 0.220 |
Why?
|
Cystatin C | 1 | 2024 | 60 | 0.220 |
Why?
|
Hyperbaric Oxygenation | 1 | 2023 | 23 | 0.220 |
Why?
|
Reproductive Techniques | 5 | 2002 | 8 | 0.210 |
Why?
|
Cystic Fibrosis | 3 | 2021 | 262 | 0.210 |
Why?
|
Practice Guidelines as Topic | 5 | 2014 | 1329 | 0.210 |
Why?
|
Health Surveys | 4 | 2016 | 258 | 0.210 |
Why?
|
DNA Damage | 2 | 2019 | 542 | 0.200 |
Why?
|
Tamoxifen | 2 | 2014 | 376 | 0.200 |
Why?
|
Aphrodisiacs | 2 | 2020 | 5 | 0.200 |
Why?
|
Diagnostic Techniques, Urological | 1 | 2002 | 5 | 0.200 |
Why?
|
Creatinine | 2 | 2024 | 423 | 0.200 |
Why?
|
Body Mass Index | 4 | 2024 | 1703 | 0.200 |
Why?
|
Reference Values | 8 | 2019 | 746 | 0.200 |
Why?
|
Suture Techniques | 1 | 2004 | 201 | 0.200 |
Why?
|
Robotic Surgical Procedures | 2 | 2018 | 225 | 0.200 |
Why?
|
Comprehensive Health Care | 1 | 2002 | 19 | 0.200 |
Why?
|
Injections | 4 | 2014 | 160 | 0.190 |
Why?
|
Sexual Dysfunctions, Psychological | 2 | 2013 | 41 | 0.190 |
Why?
|
Alprostadil | 3 | 2010 | 27 | 0.180 |
Why?
|
Forecasting | 4 | 2015 | 375 | 0.180 |
Why?
|
Adolescent | 18 | 2018 | 20480 | 0.180 |
Why?
|
Pituitary Hormone-Releasing Hormones | 4 | 1990 | 8 | 0.180 |
Why?
|
Amyloidosis | 1 | 2002 | 71 | 0.180 |
Why?
|
Animals | 37 | 2020 | 36265 | 0.180 |
Why?
|
Preoperative Care | 3 | 2014 | 371 | 0.180 |
Why?
|
Abnormalities, Multiple | 1 | 2007 | 978 | 0.170 |
Why?
|
DNA Methylation | 2 | 2020 | 1144 | 0.170 |
Why?
|
Informed Consent | 2 | 2016 | 344 | 0.170 |
Why?
|
Efficiency | 1 | 2021 | 62 | 0.170 |
Why?
|
Spermatic Cord Torsion | 2 | 1998 | 14 | 0.170 |
Why?
|
Ultrasonography | 9 | 1996 | 992 | 0.170 |
Why?
|
Embryo Transfer | 2 | 1999 | 60 | 0.170 |
Why?
|
Multiple Birth Offspring | 1 | 1999 | 6 | 0.170 |
Why?
|
Cysts | 4 | 1993 | 108 | 0.170 |
Why?
|
Professional Practice | 1 | 2020 | 43 | 0.160 |
Why?
|
Reproductive Control Agents | 1 | 2019 | 2 | 0.160 |
Why?
|
Prolactin | 2 | 2017 | 115 | 0.160 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2002 | 282 | 0.160 |
Why?
|
Symptom Assessment | 1 | 2020 | 107 | 0.160 |
Why?
|
Leydig Cell Tumor | 1 | 1999 | 7 | 0.160 |
Why?
|
DNA | 4 | 2021 | 1663 | 0.160 |
Why?
|
Electric Stimulation | 2 | 1992 | 330 | 0.160 |
Why?
|
Body Image | 1 | 2019 | 41 | 0.160 |
Why?
|
Reproductive Health Services | 1 | 2019 | 19 | 0.160 |
Why?
|
Sensitivity and Specificity | 4 | 2014 | 2162 | 0.160 |
Why?
|
Disease Management | 2 | 2015 | 555 | 0.150 |
Why?
|
Needs Assessment | 1 | 2020 | 184 | 0.150 |
Why?
|
Cachexia | 1 | 2018 | 52 | 0.150 |
Why?
|
Androgen Receptor Antagonists | 1 | 2018 | 40 | 0.150 |
Why?
|
Anastomosis, Surgical | 2 | 2009 | 168 | 0.150 |
Why?
|
Iron Overload | 1 | 2018 | 16 | 0.150 |
Why?
|
Urogenital Neoplasms | 1 | 2018 | 16 | 0.150 |
Why?
|
Prostatitis | 1 | 2018 | 14 | 0.150 |
Why?
|
Prevalence | 5 | 2019 | 2647 | 0.150 |
Why?
|
Chronobiology Disorders | 1 | 2018 | 7 | 0.150 |
Why?
|
Social Media | 1 | 2020 | 112 | 0.140 |
Why?
|
Models, Statistical | 1 | 2021 | 505 | 0.140 |
Why?
|
Urologic Diseases | 1 | 2018 | 44 | 0.140 |
Why?
|
Androgen-Binding Protein | 6 | 1986 | 26 | 0.140 |
Why?
|
North America | 1 | 2018 | 261 | 0.140 |
Why?
|
Patient Safety | 2 | 2020 | 429 | 0.140 |
Why?
|
Endothelin-1 | 1 | 2017 | 44 | 0.140 |
Why?
|
Diabetes Complications | 1 | 1999 | 207 | 0.140 |
Why?
|
Europe | 1 | 2018 | 384 | 0.140 |
Why?
|
Estrogens | 1 | 2020 | 521 | 0.140 |
Why?
|
Sulfones | 4 | 2008 | 74 | 0.140 |
Why?
|
Medical Audit | 1 | 2017 | 101 | 0.130 |
Why?
|
Urologists | 1 | 2016 | 12 | 0.130 |
Why?
|
Cause of Death | 3 | 2014 | 499 | 0.130 |
Why?
|
Dilatation, Pathologic | 1 | 2017 | 96 | 0.130 |
Why?
|
Recovery of Function | 2 | 2016 | 472 | 0.130 |
Why?
|
Endoscopy | 1 | 2019 | 289 | 0.130 |
Why?
|
Lipoproteins, HDL | 1 | 2017 | 117 | 0.130 |
Why?
|
Cytological Techniques | 1 | 1996 | 17 | 0.130 |
Why?
|
Fertilization | 2 | 2015 | 45 | 0.130 |
Why?
|
Interleukin-17 | 1 | 2017 | 130 | 0.130 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2020 | 227 | 0.130 |
Why?
|
Southwestern United States | 2 | 2016 | 44 | 0.130 |
Why?
|
Collagen | 1 | 1998 | 332 | 0.130 |
Why?
|
Mass Screening | 2 | 2015 | 831 | 0.130 |
Why?
|
Linear Models | 3 | 2013 | 724 | 0.130 |
Why?
|
Perineum | 2 | 2014 | 48 | 0.130 |
Why?
|
Graft Survival | 1 | 2018 | 557 | 0.130 |
Why?
|
Mothers | 1 | 2019 | 369 | 0.120 |
Why?
|
Complementary Therapies | 1 | 2016 | 42 | 0.120 |
Why?
|
Coitus | 3 | 2019 | 21 | 0.120 |
Why?
|
Research Design | 1 | 2020 | 757 | 0.120 |
Why?
|
Kidney Transplantation | 2 | 2018 | 681 | 0.120 |
Why?
|
Evaluation Studies as Topic | 4 | 2008 | 261 | 0.120 |
Why?
|
Embryo Loss | 1 | 2015 | 26 | 0.120 |
Why?
|
Oocytes | 1 | 1997 | 301 | 0.120 |
Why?
|
Interleukin-6 | 1 | 2017 | 452 | 0.120 |
Why?
|
Comorbidity | 3 | 2018 | 1602 | 0.120 |
Why?
|
Microinjections | 4 | 1999 | 51 | 0.120 |
Why?
|
Cost-Benefit Analysis | 3 | 2018 | 565 | 0.120 |
Why?
|
Placebos | 2 | 2015 | 240 | 0.120 |
Why?
|
Laser Therapy | 1 | 1997 | 251 | 0.120 |
Why?
|
4-Aminobenzoic Acid | 1 | 2014 | 1 | 0.110 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2017 | 340 | 0.110 |
Why?
|
Iontophoresis | 1 | 2014 | 6 | 0.110 |
Why?
|
Nicardipine | 1 | 2014 | 17 | 0.110 |
Why?
|
Verapamil | 1 | 2014 | 58 | 0.110 |
Why?
|
Colchicine | 1 | 2014 | 39 | 0.110 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 712 | 0.110 |
Why?
|
Health Services Needs and Demand | 1 | 2016 | 181 | 0.110 |
Why?
|
C-Reactive Protein | 1 | 2017 | 471 | 0.110 |
Why?
|
E2F1 Transcription Factor | 1 | 2014 | 51 | 0.110 |
Why?
|
Lung Transplantation | 1 | 2018 | 334 | 0.110 |
Why?
|
Prostate | 3 | 2014 | 449 | 0.110 |
Why?
|
Postoperative Care | 2 | 2008 | 309 | 0.110 |
Why?
|
Lithotripsy | 1 | 2014 | 27 | 0.110 |
Why?
|
Vitamin E | 1 | 2014 | 69 | 0.110 |
Why?
|
Autoantibodies | 2 | 1994 | 462 | 0.110 |
Why?
|
Aged, 80 and over | 4 | 2020 | 7184 | 0.110 |
Why?
|
Registries | 2 | 2013 | 1551 | 0.110 |
Why?
|
Reactive Oxygen Species | 2 | 2015 | 523 | 0.110 |
Why?
|
Manometry | 1 | 2014 | 69 | 0.110 |
Why?
|
Calcium Channel Blockers | 1 | 2014 | 116 | 0.110 |
Why?
|
Personal Satisfaction | 2 | 2013 | 108 | 0.110 |
Why?
|
Multivariate Analysis | 2 | 2014 | 1486 | 0.110 |
Why?
|
Confidence Intervals | 1 | 2014 | 301 | 0.110 |
Why?
|
Carnitine | 1 | 2014 | 77 | 0.110 |
Why?
|
Chronic Pain | 1 | 2016 | 139 | 0.110 |
Why?
|
California | 1 | 2014 | 141 | 0.110 |
Why?
|
Y Chromosome | 4 | 2001 | 48 | 0.110 |
Why?
|
Insemination, Artificial | 2 | 1991 | 13 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 142 | 0.110 |
Why?
|
Sexually Transmitted Diseases | 2 | 2016 | 97 | 0.110 |
Why?
|
Odds Ratio | 2 | 2014 | 1337 | 0.110 |
Why?
|
Self Report | 1 | 2016 | 551 | 0.110 |
Why?
|
Death | 1 | 2014 | 80 | 0.100 |
Why?
|
Affect | 1 | 2014 | 173 | 0.100 |
Why?
|
Homeodomain Proteins | 2 | 2014 | 585 | 0.100 |
Why?
|
Antibodies | 1 | 1995 | 382 | 0.100 |
Why?
|
Health Status | 3 | 2010 | 412 | 0.100 |
Why?
|
Sunlight | 1 | 2013 | 25 | 0.100 |
Why?
|
Peptide Fragments | 1 | 2017 | 835 | 0.100 |
Why?
|
Pain, Postoperative | 2 | 2016 | 274 | 0.100 |
Why?
|
Smoking Cessation | 1 | 2014 | 208 | 0.100 |
Why?
|
Drug Costs | 1 | 2013 | 67 | 0.100 |
Why?
|
Arteries | 1 | 2014 | 221 | 0.100 |
Why?
|
Melatonin | 1 | 2013 | 30 | 0.100 |
Why?
|
Interferon-alpha | 1 | 2014 | 248 | 0.100 |
Why?
|
Femoral Nerve | 1 | 1992 | 8 | 0.100 |
Why?
|
Osteoporotic Fractures | 1 | 2012 | 31 | 0.100 |
Why?
|
Ligation | 2 | 2012 | 137 | 0.100 |
Why?
|
Haploinsufficiency | 1 | 2014 | 274 | 0.100 |
Why?
|
Administration, Topical | 2 | 2014 | 142 | 0.100 |
Why?
|
Sperm Capacitation | 5 | 1997 | 20 | 0.100 |
Why?
|
Bupivacaine | 1 | 1992 | 27 | 0.100 |
Why?
|
Steroids | 1 | 2013 | 209 | 0.100 |
Why?
|
Laparoscopy | 4 | 2008 | 513 | 0.100 |
Why?
|
Disorders of Sex Development | 1 | 2012 | 72 | 0.090 |
Why?
|
Apoptosis | 5 | 1999 | 1931 | 0.090 |
Why?
|
Anesthesia, Local | 1 | 1992 | 44 | 0.090 |
Why?
|
Patient Selection | 3 | 2004 | 731 | 0.090 |
Why?
|
Analysis of Variance | 2 | 2012 | 1047 | 0.090 |
Why?
|
Klinefelter Syndrome | 1 | 2011 | 18 | 0.090 |
Why?
|
Blood Pressure | 2 | 2015 | 1408 | 0.090 |
Why?
|
Brachytherapy | 1 | 2012 | 92 | 0.090 |
Why?
|
Life Style | 1 | 2014 | 453 | 0.090 |
Why?
|
Heart Transplantation | 1 | 2018 | 885 | 0.090 |
Why?
|
Sarcoma, Ewing | 1 | 1992 | 118 | 0.090 |
Why?
|
Hot Temperature | 1 | 1992 | 146 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 1997 | 1352 | 0.090 |
Why?
|
Chromosome Deletion | 3 | 2013 | 663 | 0.090 |
Why?
|
Prenatal Diagnosis | 1 | 2016 | 627 | 0.090 |
Why?
|
Recombinant Proteins | 1 | 2015 | 1439 | 0.090 |
Why?
|
Karyotyping | 2 | 2013 | 324 | 0.090 |
Why?
|
Deficiency Diseases | 1 | 2011 | 11 | 0.090 |
Why?
|
Micromanipulation | 1 | 1991 | 1 | 0.090 |
Why?
|
Vitamin D | 1 | 2013 | 177 | 0.090 |
Why?
|
Soft Tissue Neoplasms | 1 | 1992 | 126 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 1133 | 0.090 |
Why?
|
Hydrocarbons, Halogenated | 2 | 1981 | 5 | 0.090 |
Why?
|
Antinematodal Agents | 2 | 1981 | 11 | 0.090 |
Why?
|
Pseudogenes | 1 | 2011 | 53 | 0.090 |
Why?
|
Stem Cells | 1 | 2016 | 750 | 0.090 |
Why?
|
Genetic Markers | 3 | 2014 | 630 | 0.090 |
Why?
|
Propane | 2 | 1981 | 28 | 0.090 |
Why?
|
Sterilization, Tubal | 1 | 2010 | 15 | 0.090 |
Why?
|
Circadian Rhythm | 1 | 2013 | 289 | 0.090 |
Why?
|
Cyclophosphamide | 1 | 1992 | 417 | 0.090 |
Why?
|
Patient Compliance | 2 | 2011 | 480 | 0.090 |
Why?
|
Sarcoma | 1 | 1992 | 200 | 0.080 |
Why?
|
Insemination, Artificial, Heterologous | 1 | 1990 | 2 | 0.080 |
Why?
|
Transition to Adult Care | 1 | 2012 | 119 | 0.080 |
Why?
|
Data Collection | 2 | 2011 | 396 | 0.080 |
Why?
|
Public Health | 1 | 2012 | 286 | 0.080 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 1475 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 3836 | 0.080 |
Why?
|
Cricetinae | 10 | 2000 | 398 | 0.080 |
Why?
|
Medication Adherence | 1 | 2013 | 338 | 0.080 |
Why?
|
Marital Status | 1 | 2009 | 32 | 0.080 |
Why?
|
Postoperative Complications | 3 | 2005 | 3204 | 0.080 |
Why?
|
Models, Biological | 1 | 1995 | 1533 | 0.080 |
Why?
|
Motor Activity | 1 | 2013 | 537 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2018 | 1118 | 0.080 |
Why?
|
Physician-Patient Relations | 1 | 2013 | 444 | 0.080 |
Why?
|
Brain Death | 1 | 2010 | 75 | 0.080 |
Why?
|
Interdisciplinary Communication | 1 | 2010 | 134 | 0.080 |
Why?
|
Substance Withdrawal Syndrome | 1 | 1990 | 149 | 0.080 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 774 | 0.080 |
Why?
|
Sex Factors | 2 | 2010 | 1374 | 0.080 |
Why?
|
Intraoperative Care | 1 | 2009 | 120 | 0.080 |
Why?
|
Cooperative Behavior | 1 | 2010 | 229 | 0.080 |
Why?
|
Infant, Newborn | 2 | 2019 | 8560 | 0.080 |
Why?
|
Statistics as Topic | 1 | 2009 | 262 | 0.080 |
Why?
|
Darkness | 1 | 2008 | 26 | 0.080 |
Why?
|
Proteins | 2 | 2012 | 1087 | 0.080 |
Why?
|
Urethra | 1 | 2008 | 90 | 0.070 |
Why?
|
Sus scrofa | 1 | 2008 | 126 | 0.070 |
Why?
|
Peptides | 2 | 2003 | 861 | 0.070 |
Why?
|
Carrier Proteins | 3 | 1985 | 1060 | 0.070 |
Why?
|
Longevity | 1 | 2009 | 158 | 0.070 |
Why?
|
Algorithms | 1 | 2015 | 1726 | 0.070 |
Why?
|
Genome, Human | 1 | 2014 | 1347 | 0.070 |
Why?
|
Poly T | 1 | 2007 | 3 | 0.070 |
Why?
|
Ethics, Medical | 1 | 2010 | 403 | 0.070 |
Why?
|
Sildenafil Citrate | 3 | 2008 | 56 | 0.070 |
Why?
|
Arginine | 2 | 2020 | 349 | 0.070 |
Why?
|
Purines | 3 | 2008 | 119 | 0.070 |
Why?
|
Models, Animal | 1 | 2008 | 480 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2014 | 3471 | 0.070 |
Why?
|
Constriction, Pathologic | 3 | 1993 | 241 | 0.070 |
Why?
|
Maternal Age | 2 | 2016 | 138 | 0.060 |
Why?
|
Internet | 2 | 2019 | 393 | 0.060 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 2294 | 0.060 |
Why?
|
Patient Care Team | 1 | 2010 | 570 | 0.060 |
Why?
|
Breast Neoplasms | 1 | 2018 | 2762 | 0.060 |
Why?
|
Statistics, Nonparametric | 2 | 2019 | 454 | 0.060 |
Why?
|
Spermatocytes | 3 | 1999 | 23 | 0.060 |
Why?
|
Ovum | 4 | 1997 | 17 | 0.060 |
Why?
|
X Chromosome | 2 | 2001 | 342 | 0.060 |
Why?
|
Polypropylenes | 1 | 2005 | 16 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 2932 | 0.060 |
Why?
|
Foreign-Body Reaction | 1 | 2005 | 17 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2020 | 1666 | 0.060 |
Why?
|
Hernia, Inguinal | 1 | 2005 | 43 | 0.060 |
Why?
|
Surgical Mesh | 1 | 2005 | 68 | 0.060 |
Why?
|
Critical Care | 1 | 2010 | 680 | 0.060 |
Why?
|
Intestines | 1 | 2008 | 612 | 0.060 |
Why?
|
Hypertrophy | 1 | 2024 | 104 | 0.060 |
Why?
|
Radionuclide Imaging | 3 | 1980 | 158 | 0.060 |
Why?
|
Kidney Function Tests | 1 | 2024 | 134 | 0.050 |
Why?
|
Depression | 1 | 2013 | 1344 | 0.050 |
Why?
|
Genital Diseases, Male | 4 | 1993 | 12 | 0.050 |
Why?
|
Nurses | 1 | 2004 | 74 | 0.050 |
Why?
|
Quality Control | 3 | 1995 | 129 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2019 | 3057 | 0.050 |
Why?
|
Prognosis | 3 | 2004 | 5065 | 0.050 |
Why?
|
Rats | 8 | 1997 | 3874 | 0.050 |
Why?
|
Endocrine System Diseases | 1 | 2003 | 46 | 0.050 |
Why?
|
Base Pair Mismatch | 1 | 2003 | 22 | 0.050 |
Why?
|
Disease Progression | 2 | 2025 | 2231 | 0.050 |
Why?
|
Neoplasm Grading | 2 | 2015 | 302 | 0.050 |
Why?
|
Obesity | 1 | 2014 | 2405 | 0.050 |
Why?
|
Developmental Disabilities | 1 | 2008 | 733 | 0.050 |
Why?
|
Imipramine | 2 | 1973 | 18 | 0.050 |
Why?
|
Sex Chromosome Disorders of Sex Development | 2 | 2013 | 13 | 0.050 |
Why?
|
Sex Chromosome Aberrations | 2 | 2013 | 60 | 0.050 |
Why?
|
Imidazoles | 1 | 2003 | 218 | 0.050 |
Why?
|
Microsatellite Repeats | 1 | 2003 | 239 | 0.050 |
Why?
|
Transferrin | 5 | 1985 | 50 | 0.050 |
Why?
|
Chlorohydrins | 1 | 1981 | 1 | 0.050 |
Why?
|
Epichlorohydrin | 1 | 1981 | 1 | 0.050 |
Why?
|
Chemical Industry | 1 | 1981 | 7 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 1399 | 0.050 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2001 | 64 | 0.050 |
Why?
|
Environmental Exposure | 2 | 1981 | 244 | 0.050 |
Why?
|
Ovulation Induction | 2 | 2018 | 42 | 0.050 |
Why?
|
Muscular Atrophy, Spinal | 1 | 2001 | 45 | 0.050 |
Why?
|
Glutamine | 1 | 2003 | 222 | 0.050 |
Why?
|
Sural Nerve | 1 | 2001 | 47 | 0.050 |
Why?
|
Community Health Services | 1 | 2002 | 92 | 0.050 |
Why?
|
Benchmarking | 1 | 2002 | 148 | 0.040 |
Why?
|
Pregnancy, Multiple | 1 | 2001 | 48 | 0.040 |
Why?
|
Polymorphism, Genetic | 2 | 2001 | 896 | 0.040 |
Why?
|
Cyclic AMP | 2 | 1998 | 260 | 0.040 |
Why?
|
Vascular Surgical Procedures | 1 | 2006 | 560 | 0.040 |
Why?
|
Regression Analysis | 2 | 1994 | 832 | 0.040 |
Why?
|
Medical Laboratory Personnel | 1 | 2000 | 10 | 0.040 |
Why?
|
Medical Oncology | 1 | 2002 | 243 | 0.040 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 1977 | 85 | 0.040 |
Why?
|
Hormones | 1 | 2001 | 195 | 0.040 |
Why?
|
Health Policy | 1 | 2002 | 228 | 0.040 |
Why?
|
Phytotherapy | 1 | 2020 | 52 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 1999 | 2157 | 0.040 |
Why?
|
Panax | 1 | 2019 | 7 | 0.040 |
Why?
|
Orgasm | 1 | 2019 | 7 | 0.040 |
Why?
|
Survivors | 1 | 2002 | 360 | 0.040 |
Why?
|
Nondisjunction, Genetic | 1 | 1999 | 22 | 0.040 |
Why?
|
DNA Repair | 1 | 2003 | 627 | 0.040 |
Why?
|
Video Recording | 1 | 2020 | 202 | 0.040 |
Why?
|
Centrifugation | 1 | 1998 | 25 | 0.040 |
Why?
|
Commerce | 1 | 2019 | 58 | 0.040 |
Why?
|
Syndrome | 2 | 2016 | 1148 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 183 | 0.040 |
Why?
|
Cells, Cultured | 7 | 2014 | 3171 | 0.040 |
Why?
|
Mitoxantrone | 1 | 1997 | 27 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2000 | 310 | 0.040 |
Why?
|
Transplant Recipients | 1 | 2019 | 225 | 0.040 |
Why?
|
Zygote Intrafallopian Transfer | 1 | 1997 | 1 | 0.040 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 1050 | 0.040 |
Why?
|
Necrosis | 1 | 1998 | 221 | 0.040 |
Why?
|
Plant Extracts | 1 | 2019 | 141 | 0.040 |
Why?
|
Medical Laboratory Science | 1 | 1997 | 13 | 0.040 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 1998 | 171 | 0.030 |
Why?
|
Yohimbine | 1 | 1997 | 18 | 0.030 |
Why?
|
Methods | 4 | 1990 | 144 | 0.030 |
Why?
|
Equipment Design | 2 | 2016 | 611 | 0.030 |
Why?
|
DNA Copy Number Variations | 2 | 2014 | 1021 | 0.030 |
Why?
|
History, 21st Century | 1 | 2018 | 278 | 0.030 |
Why?
|
Ultrasonography, Interventional | 1 | 2019 | 204 | 0.030 |
Why?
|
Lymph | 1 | 1976 | 25 | 0.030 |
Why?
|
Patient Reported Outcome Measures | 1 | 2019 | 202 | 0.030 |
Why?
|
Repressor Proteins | 2 | 1999 | 866 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 1997 | 165 | 0.030 |
Why?
|
Child | 6 | 2012 | 25678 | 0.030 |
Why?
|
Fatty Acids | 1 | 2019 | 369 | 0.030 |
Why?
|
Vincristine | 2 | 1997 | 195 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2002 | 1964 | 0.030 |
Why?
|
Sexual Behavior, Animal | 1 | 2016 | 88 | 0.030 |
Why?
|
Organ Size | 2 | 2010 | 468 | 0.030 |
Why?
|
Education, Medical | 1 | 2000 | 298 | 0.030 |
Why?
|
Bacteriuria | 2 | 1973 | 48 | 0.030 |
Why?
|
Inhalation | 1 | 1995 | 8 | 0.030 |
Why?
|
Weight Lifting | 1 | 1995 | 6 | 0.030 |
Why?
|
Gonadotropins, Pituitary | 2 | 1987 | 4 | 0.030 |
Why?
|
Logistic Models | 3 | 2010 | 1903 | 0.030 |
Why?
|
User-Computer Interface | 1 | 2016 | 165 | 0.030 |
Why?
|
Internship and Residency | 2 | 2016 | 1249 | 0.030 |
Why?
|
Dacarbazine | 2 | 1992 | 99 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 1999 | 612 | 0.030 |
Why?
|
Hodgkin Disease | 1 | 1997 | 301 | 0.030 |
Why?
|
Pilot Projects | 2 | 2016 | 1484 | 0.030 |
Why?
|
Dronabinol | 2 | 1986 | 33 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 169 | 0.030 |
Why?
|
Chromosome Disorders | 1 | 1997 | 315 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2005 | 1844 | 0.030 |
Why?
|
Discoidin Domain Receptor 1 | 1 | 2014 | 8 | 0.030 |
Why?
|
Immunologic Tests | 1 | 1994 | 20 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2014 | 1760 | 0.030 |
Why?
|
In Vitro Techniques | 6 | 1986 | 992 | 0.030 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 250 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1999 | 793 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 1997 | 1304 | 0.030 |
Why?
|
Pituitary Hormones | 1 | 2013 | 4 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1997 | 624 | 0.030 |
Why?
|
Urinary Tract Infections | 2 | 1974 | 243 | 0.030 |
Why?
|
Doxorubicin | 2 | 1992 | 305 | 0.030 |
Why?
|
Receptors, Adrenergic | 1 | 1973 | 28 | 0.030 |
Why?
|
Glomerulonephritis | 1 | 1974 | 78 | 0.030 |
Why?
|
Species Specificity | 1 | 2014 | 571 | 0.030 |
Why?
|
Gene Deletion | 1 | 1997 | 809 | 0.030 |
Why?
|
Buffers | 2 | 1991 | 32 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 1994 | 216 | 0.030 |
Why?
|
Pneumonia, Pneumococcal | 1 | 1974 | 86 | 0.030 |
Why?
|
Receptors, FSH | 2 | 1991 | 20 | 0.030 |
Why?
|
CpG Islands | 1 | 2014 | 347 | 0.030 |
Why?
|
Hematocrit | 1 | 2013 | 116 | 0.030 |
Why?
|
Quinacrine | 2 | 1992 | 3 | 0.020 |
Why?
|
Repetitive Sequences, Amino Acid | 2 | 2003 | 19 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 2 | 1982 | 153 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 541 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 4 | 1990 | 1730 | 0.020 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 1992 | 92 | 0.020 |
Why?
|
Pneumococcal Infections | 1 | 1974 | 276 | 0.020 |
Why?
|
False Negative Reactions | 2 | 1991 | 90 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 907 | 0.020 |
Why?
|
Hemoglobins | 1 | 2013 | 323 | 0.020 |
Why?
|
Lipids | 1 | 2015 | 566 | 0.020 |
Why?
|
Rectum | 1 | 1992 | 113 | 0.020 |
Why?
|
Health Expenditures | 1 | 2012 | 116 | 0.020 |
Why?
|
Genetic Therapy | 1 | 2016 | 727 | 0.020 |
Why?
|
Short Stature Homeobox Protein | 1 | 2011 | 11 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2011 | 141 | 0.020 |
Why?
|
Nerve Block | 1 | 1992 | 67 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1992 | 138 | 0.020 |
Why?
|
Pituitary Function Tests | 1 | 1990 | 3 | 0.020 |
Why?
|
Calcinosis | 1 | 1992 | 193 | 0.020 |
Why?
|
Seminiferous Tubules | 2 | 1987 | 15 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2014 | 1413 | 0.020 |
Why?
|
Blood Specimen Collection | 1 | 1990 | 48 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 751 | 0.020 |
Why?
|
Global Health | 1 | 1995 | 612 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2010 | 129 | 0.020 |
Why?
|
Prostatic Diseases | 1 | 1989 | 15 | 0.020 |
Why?
|
Hepatitis, Viral, Human | 1 | 1990 | 45 | 0.020 |
Why?
|
Sexuality | 1 | 2009 | 13 | 0.020 |
Why?
|
Body Height | 1 | 2011 | 231 | 0.020 |
Why?
|
Program Development | 1 | 2010 | 187 | 0.020 |
Why?
|
Rats, Inbred Strains | 3 | 1986 | 236 | 0.020 |
Why?
|
gamma-Glutamyltransferase | 3 | 1986 | 48 | 0.020 |
Why?
|
Comparative Genomic Hybridization | 1 | 2011 | 577 | 0.020 |
Why?
|
Fructose | 1 | 1989 | 62 | 0.020 |
Why?
|
Spermatids | 2 | 1999 | 27 | 0.020 |
Why?
|
Survival Analysis | 1 | 2012 | 1596 | 0.020 |
Why?
|
Cyclic AMP Response Element Modulator | 2 | 1999 | 25 | 0.020 |
Why?
|
Preservation, Biological | 2 | 1985 | 10 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1990 | 244 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 2003 | 1632 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 1834 | 0.020 |
Why?
|
Self Concept | 1 | 2009 | 160 | 0.020 |
Why?
|
Growth Substances | 1 | 1988 | 116 | 0.020 |
Why?
|
Sympathomimetics | 1 | 1987 | 13 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 1990 | 228 | 0.020 |
Why?
|
Sclerosis | 1 | 1987 | 38 | 0.020 |
Why?
|
Genetic Variation | 1 | 2014 | 1610 | 0.020 |
Why?
|
Bicarbonates | 1 | 1987 | 100 | 0.020 |
Why?
|
Hyperprolactinemia | 1 | 1987 | 22 | 0.020 |
Why?
|
Thyroid Diseases | 1 | 1987 | 34 | 0.020 |
Why?
|
Sodium Bicarbonate | 1 | 1987 | 58 | 0.020 |
Why?
|
Radiography | 1 | 1989 | 826 | 0.020 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 1987 | 71 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 1987 | 237 | 0.020 |
Why?
|
Biomarkers, Tumor | 1 | 2015 | 1705 | 0.020 |
Why?
|
Mesocricetus | 2 | 2000 | 74 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 3 | 1986 | 312 | 0.020 |
Why?
|
Osteosarcoma | 1 | 1989 | 265 | 0.020 |
Why?
|
Sodium | 1 | 1987 | 307 | 0.020 |
Why?
|
Functional Laterality | 1 | 1986 | 196 | 0.020 |
Why?
|
Sampling Studies | 1 | 2005 | 78 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 2658 | 0.010 |
Why?
|
Microscopy, Electron | 2 | 1982 | 374 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 1987 | 278 | 0.010 |
Why?
|
Phenotype | 1 | 2014 | 4518 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 1989 | 461 | 0.010 |
Why?
|
Vardenafil Dihydrochloride | 1 | 2003 | 1 | 0.010 |
Why?
|
Technetium | 2 | 1974 | 15 | 0.010 |
Why?
|
Triazines | 1 | 2003 | 32 | 0.010 |
Why?
|
Cannabinoids | 1 | 1983 | 33 | 0.010 |
Why?
|
Depression, Chemical | 1 | 1982 | 43 | 0.010 |
Why?
|
Transsexualism | 1 | 1982 | 14 | 0.010 |
Why?
|
Mice | 2 | 2014 | 18815 | 0.010 |
Why?
|
Adrenergic alpha-Antagonists | 2 | 1973 | 39 | 0.010 |
Why?
|
Cattle | 2 | 1993 | 587 | 0.010 |
Why?
|
Tissue and Organ Harvesting | 1 | 2002 | 40 | 0.010 |
Why?
|
Androgen-Insensitivity Syndrome | 1 | 2001 | 27 | 0.010 |
Why?
|
DNA Primers | 1 | 2003 | 671 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 1982 | 433 | 0.010 |
Why?
|
Reoperation | 1 | 2005 | 864 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1984 | 835 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 1985 | 403 | 0.010 |
Why?
|
Singapore | 1 | 2001 | 17 | 0.010 |
Why?
|
Dogs | 2 | 1973 | 798 | 0.010 |
Why?
|
Fertility Agents, Female | 1 | 2001 | 9 | 0.010 |
Why?
|
Licensure | 1 | 2001 | 15 | 0.010 |
Why?
|
Codon | 1 | 2001 | 108 | 0.010 |
Why?
|
Flushing | 1 | 2000 | 6 | 0.010 |
Why?
|
Dizziness | 1 | 2000 | 28 | 0.010 |
Why?
|
Nose | 1 | 2000 | 98 | 0.010 |
Why?
|
Headache | 1 | 2000 | 111 | 0.010 |
Why?
|
Dyspepsia | 1 | 2000 | 107 | 0.010 |
Why?
|
Vision, Ocular | 1 | 2000 | 137 | 0.010 |
Why?
|
Autoradiography | 1 | 1999 | 74 | 0.010 |
Why?
|
Exons | 1 | 2001 | 833 | 0.010 |
Why?
|
bcl-2-Associated X Protein | 1 | 1999 | 73 | 0.010 |
Why?
|
Prostaglandins | 1 | 1978 | 47 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 1999 | 130 | 0.010 |
Why?
|
Tissue Donors | 1 | 2002 | 522 | 0.010 |
Why?
|
Geography | 1 | 1998 | 124 | 0.010 |
Why?
|
Body Weight | 1 | 1982 | 1032 | 0.010 |
Why?
|
Histocytological Preparation Techniques | 1 | 1997 | 5 | 0.010 |
Why?
|
Norepinephrine | 2 | 1980 | 175 | 0.010 |
Why?
|
Vinblastine | 1 | 1997 | 59 | 0.010 |
Why?
|
Secretory Rate | 1 | 1977 | 2 | 0.010 |
Why?
|
Kinetics | 3 | 1985 | 1350 | 0.010 |
Why?
|
Chromatography, Ion Exchange | 1 | 1977 | 67 | 0.010 |
Why?
|
Meiosis | 1 | 1998 | 115 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1998 | 260 | 0.010 |
Why?
|
Cytosol | 1 | 1977 | 168 | 0.010 |
Why?
|
Prednisone | 1 | 1997 | 290 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 1999 | 464 | 0.010 |
Why?
|
Cell Count | 1 | 1977 | 255 | 0.010 |
Why?
|
Guinea Pigs | 1 | 1976 | 170 | 0.010 |
Why?
|
Atrophy | 1 | 1977 | 250 | 0.010 |
Why?
|
Bucladesine | 2 | 1986 | 21 | 0.010 |
Why?
|
Muscle Contraction | 2 | 1980 | 196 | 0.010 |
Why?
|
Plastics | 1 | 1995 | 14 | 0.010 |
Why?
|
Child, Preschool | 3 | 1977 | 14748 | 0.010 |
Why?
|
Iodohippuric Acid | 1 | 1974 | 2 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 1976 | 692 | 0.010 |
Why?
|
Craniopharyngioma | 1 | 1994 | 35 | 0.010 |
Why?
|
Hyalin | 1 | 1974 | 6 | 0.010 |
Why?
|
Iodine Radioisotopes | 1 | 1974 | 80 | 0.010 |
Why?
|
Blood Urea Nitrogen | 1 | 1974 | 77 | 0.010 |
Why?
|
Rabbits | 1 | 1995 | 735 | 0.010 |
Why?
|
Uremia | 1 | 1974 | 36 | 0.010 |
Why?
|
Mestranol | 1 | 1973 | 2 | 0.010 |
Why?
|
Ethynodiol Diacetate | 1 | 1973 | 2 | 0.010 |
Why?
|
Phentolamine | 1 | 1973 | 20 | 0.010 |
Why?
|
Parasympatholytics | 1 | 1973 | 10 | 0.010 |
Why?
|
Spinal Cord Neoplasms | 1 | 1994 | 71 | 0.010 |
Why?
|
Parasympathetic Nervous System | 1 | 1973 | 15 | 0.010 |
Why?
|
Fibrin | 1 | 1974 | 65 | 0.010 |
Why?
|
Atropine | 1 | 1973 | 31 | 0.010 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 1974 | 68 | 0.010 |
Why?
|
Kidney Glomerulus | 1 | 1974 | 84 | 0.010 |
Why?
|
Transducers | 1 | 1973 | 26 | 0.010 |
Why?
|
Proteinuria | 1 | 1974 | 113 | 0.010 |
Why?
|
Pituitary Neoplasms | 1 | 1994 | 84 | 0.010 |
Why?
|
Contraceptives, Oral | 1 | 1973 | 41 | 0.010 |
Why?
|
Sympathetic Nervous System | 1 | 1973 | 67 | 0.010 |
Why?
|
Protein Binding | 1 | 1977 | 1831 | 0.010 |
Why?
|
Stimulation, Chemical | 2 | 1986 | 66 | 0.010 |
Why?
|
Electromyography | 1 | 1973 | 175 | 0.010 |
Why?
|
Sulfur | 1 | 1972 | 13 | 0.010 |
Why?
|
Colloids | 1 | 1972 | 17 | 0.010 |
Why?
|
Urination | 1 | 1972 | 26 | 0.010 |
Why?
|
1-Methyl-3-isobutylxanthine | 2 | 1984 | 14 | 0.010 |
Why?
|
Cystitis | 1 | 1972 | 44 | 0.010 |
Why?
|
Cell Nucleus | 2 | 1985 | 688 | 0.010 |
Why?
|
Streptococcus pneumoniae | 1 | 1974 | 383 | 0.010 |
Why?
|
Staining and Labeling | 1 | 1992 | 187 | 0.010 |
Why?
|
Radioligand Assay | 1 | 1991 | 27 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1991 | 111 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 1992 | 337 | 0.010 |
Why?
|
Chronic Disease | 1 | 1974 | 1252 | 0.010 |
Why?
|
Sepsis | 1 | 1974 | 524 | 0.000 |
Why?
|
Acute Disease | 1 | 1992 | 1184 | 0.000 |
Why?
|
Sex Preselection | 1 | 1988 | 6 | 0.000 |
Why?
|
Metaphase | 1 | 1988 | 35 | 0.000 |
Why?
|
Mitogens | 1 | 1988 | 32 | 0.000 |
Why?
|
Blood | 1 | 1988 | 105 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 1998 | 4746 | 0.000 |
Why?
|
Culture Media | 1 | 1988 | 184 | 0.000 |
Why?
|
Cisplatin | 1 | 1989 | 284 | 0.000 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1988 | 363 | 0.000 |
Why?
|
Kidney | 1 | 1974 | 1405 | 0.000 |
Why?
|
Fluorescent Dyes | 1 | 1988 | 270 | 0.000 |
Why?
|
Cell Division | 1 | 1988 | 772 | 0.000 |
Why?
|
Plasminogen Activators | 1 | 1986 | 21 | 0.000 |
Why?
|
Lung | 1 | 1974 | 1558 | 0.000 |
Why?
|
Intradermal Tests | 1 | 1985 | 2 | 0.000 |
Why?
|
Histamine | 1 | 1985 | 49 | 0.000 |
Why?
|
Hydroxyapatites | 1 | 1985 | 3 | 0.000 |
Why?
|
Adsorption | 1 | 1985 | 37 | 0.000 |
Why?
|
Diabetic Neuropathies | 1 | 1985 | 62 | 0.000 |
Why?
|
Cold Temperature | 1 | 1985 | 86 | 0.000 |
Why?
|
Filtration | 1 | 1985 | 24 | 0.000 |
Why?
|
Ethanolamines | 1 | 1985 | 31 | 0.000 |
Why?
|
Heterochromatin | 1 | 1985 | 49 | 0.000 |
Why?
|
Zona Pellucida | 1 | 1984 | 12 | 0.000 |
Why?
|
RNA, Ribosomal | 1 | 1985 | 62 | 0.000 |
Why?
|
Brain Neoplasms | 1 | 1994 | 1390 | 0.000 |
Why?
|
Inhibins | 1 | 1985 | 87 | 0.000 |
Why?
|
Cannabinol | 1 | 1983 | 1 | 0.000 |
Why?
|
Transglutaminases | 1 | 1983 | 27 | 0.000 |
Why?
|
Acyltransferases | 1 | 1983 | 47 | 0.000 |
Why?
|
Cannabidiol | 1 | 1983 | 22 | 0.000 |
Why?
|
Cell Line | 1 | 1988 | 2842 | 0.000 |
Why?
|
Cell Survival | 1 | 1985 | 892 | 0.000 |
Why?
|
Receptors, Cell Surface | 1 | 1985 | 495 | 0.000 |
Why?
|
Adrenergic Fibers | 1 | 1980 | 4 | 0.000 |
Why?
|
Cholinergic Fibers | 1 | 1980 | 9 | 0.000 |
Why?
|
Acetylcholinesterase | 1 | 1980 | 26 | 0.000 |
Why?
|
Acetylcholine | 1 | 1980 | 85 | 0.000 |
Why?
|
Doppler Effect | 1 | 1979 | 4 | 0.000 |
Why?
|
Prostaglandins A | 1 | 1978 | 1 | 0.000 |
Why?
|
Prostaglandins E | 1 | 1978 | 9 | 0.000 |
Why?
|
Prostaglandins F | 1 | 1978 | 9 | 0.000 |
Why?
|
Sperm Agglutination | 1 | 1978 | 3 | 0.000 |
Why?
|
Drug Synergism | 1 | 1978 | 239 | 0.000 |
Why?
|
Viscosity | 1 | 1978 | 43 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1985 | 2896 | 0.000 |
Why?
|
Sperm Maturation | 1 | 1978 | 13 | 0.000 |
Why?
|
Sheep | 1 | 1978 | 235 | 0.000 |
Why?
|
Ultrasonics | 1 | 1977 | 39 | 0.000 |
Why?
|
Veins | 1 | 1977 | 108 | 0.000 |
Why?
|
Intrauterine Devices | 1 | 1973 | 14 | 0.000 |
Why?
|
Pennsylvania | 1 | 1973 | 60 | 0.000 |
Why?
|
Klebsiella Infections | 1 | 1973 | 63 | 0.000 |
Why?
|
Urinary Tract | 1 | 1973 | 64 | 0.000 |
Why?
|
Drug Combinations | 1 | 1973 | 281 | 0.000 |
Why?
|
Escherichia coli Infections | 1 | 1973 | 187 | 0.000 |
Why?
|